Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia
出版年份 2022 全文链接
标题
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia
作者
关键词
-
出版物
Cancers
Volume 14, Issue 14, Pages 3300
出版商
MDPI AG
发表日期
2022-07-07
DOI
10.3390/cancers14143300
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- hnRNPK/Beclin1 signaling regulates autophagy to promote imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia cells
- (2022) JinFang Zhang et al. EXPERIMENTAL HEMATOLOGY
- Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells
- (2022) Buket Ozel et al. MEDICAL ONCOLOGY
- BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
- (2022) Gustavo P. Amarante-Mendes et al. Pharmaceutics
- Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
- (2021) Priyanka Singh et al. MEDICAL ONCOLOGY
- The application of BH3 mimetics in myeloid leukemias
- (2021) Narissa Parry et al. Cell Death & Disease
- Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes
- (2021) Anusha et al. Cell Death & Disease
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- (2021) Valentín Garcia-Gutiérrez et al. Blood Cancer Journal
- Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors
- (2021) Chen Li et al. Clinical Epigenetics
- Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
- (2021) Hui Mu et al. Frontiers in Oncology
- Impact of frontline treatment approach on outcomes of myeloid blast phase CML
- (2021) Kapil Saxena et al. Journal of Hematology & Oncology
- Review of Venetoclax in CLL, AML and Multiple Myeloma
- (2021) Masa Lasica et al. Journal of Personalized Medicine
- Chronic myeloid leukemia stem cells: targeting therapeutic implications
- (2021) Hanieh Mojtahedi et al. Stem Cell Research & Therapy
- Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex
- (2020) Youn-Sang Jung et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
- (2020) G. A. Horne et al. LEUKEMIA
- Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
- (2020) Marie Brachet-Botineau et al. Cancers
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
- (2020) Abhishek Maiti et al. ACTA HAEMATOLOGICA
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- Treatment-free remission in patients with chronic myeloid leukaemia
- (2020) David M. Ross et al. Nature Reviews Clinical Oncology
- Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia
- (2020) Ilaria S. Pagani et al. LEUKEMIA & LYMPHOMA
- Signalling input from divergent pathways subverts B cell transformation
- (2020) Lai N. Chan et al. NATURE
- Targeting the Wnt/β-catenin signaling pathway in cancer
- (2020) Ya Zhang et al. Journal of Hematology & Oncology
- Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
- (2019) Chodimella Chandrasekhar et al. Scientific Reports
- Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
- (2019) Sylwia Flis et al. Drug Design Development and Therapy
- Interferons α and β in cancer: therapeutic opportunities from new insights
- (2019) Ernest C. Borden NATURE REVIEWS DRUG DISCOVERY
- Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
- (2019) Maja Kim Kuepper et al. LEUKEMIA
- Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions
- (2019) Katharina Rothe et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications
- (2019) Francesca Nazio et al. CELL DEATH AND DIFFERENTIATION
- AKT as a Therapeutic Target for Cancer
- (2019) Mengqiu Song et al. CANCER RESEARCH
- Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
- (2019) Amanda Mogul et al. ANNALS OF PHARMACOTHERAPY
- Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia
- (2019) Rui Wang et al. MEDICINE
- Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL
- (2019) Jiu-Yu Zhan et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
- (2019) Susan Branford et al. LEUKEMIA
- Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”
- (2019) Danilo Perrotti et al. Science Translational Medicine
- BCR: a promiscuous fusion partner in hematopoietic disorders
- (2019) Malalage N. Peiris et al. Oncotarget
- Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
- (2019) Marjan Yaghmaie et al. Current Hematologic Malignancy Reports
- BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
- (2019) Federica Loscocco et al. Frontiers in Oncology
- Rapamycin for longevity: opinion article
- (2019) Mikhail V. Blagosklonny Aging-US
- Hedgehog Signaling: An Achilles’ Heel in Cancer
- (2019) Madiha Niyaz et al. Translational Oncology
- The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
- (2019) Naranie Shanmuganathan et al. Current Hematologic Malignancy Reports
- Management of Chronic Myeloid Leukemia in Advanced Phase
- (2019) Massimiliano Bonifacio et al. Frontiers in Oncology
- Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia
- (2018) Kenta Yagi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Therapeutic targeting of PP2A
- (2018) Caitlin M. O’Connor et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
- (2018) Ernest S. Han et al. Oncotarget
- The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
- (2018) Laura N. Eadie et al. Oncotarget
- Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
- (2018) Elena Arrigoni et al. Stem Cells Translational Medicine
- Targeting PP2A in cancer: Combination therapies
- (2018) Sahar Mazhar et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2018) Jerald P. Radich et al. Journal of the National Comprehensive Cancer Network
- Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
- (2018) Pablo Baquero et al. LEUKEMIA
- “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
- (2018) Emira Bousoik et al. Frontiers in Oncology
- Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
- (2018) David M. Ross et al. LEUKEMIA
- A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
- (2018) Kendra Sweet et al. LEUKEMIA RESEARCH
- A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
- (2018) Raquel Vinhas et al. OncoTargets and Therapy
- Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
- (2017) Stein-Erik Gullaksen et al. HAEMATOLOGICA
- Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
- (2017) Ami B. Patel et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
- (2017) Rebecca Mitchell et al. JNCI-Journal of the National Cancer Institute
- Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
- (2017) W Qiang et al. LEUKEMIA
- Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
- (2017) H Zhou et al. LEUKEMIA
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
- (2017) Alice Giustacchini et al. NATURE MEDICINE
- Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
- (2017) E Togasaki et al. Blood Cancer Journal
- Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
- (2017) Massimo Breccia et al. Oncotarget
- Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
- (2017) Stein-Erik Gullaksen et al. HAEMATOLOGICA
- Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
- (2017) Rebecca Mitchell et al. JNCI-Journal of the National Cancer Institute
- Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways
- (2017) Atul Kumar et al. Scientific Reports
- ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells
- (2016) Maria Karvela et al. Autophagy
- Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
- (2016) TaeHyung Kim et al. BLOOD
- Somatic mosaicism in chronic myeloid leukemia in remission
- (2016) K. Mitani et al. BLOOD
- A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2016) M Wagle et al. LEUKEMIA
- The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
- (2016) L N Eadie et al. LEUKEMIA
- Wnt signaling in cancer
- (2016) T Zhan et al. ONCOGENE
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
- (2016) M. T. Scott et al. Cancer Discovery
- Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2
- (2016) H. Xie et al. Cancer Discovery
- Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
- (2016) Tadas Rimkus et al. Cancers
- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- GLI2 inhibition abrogates human leukemia stem cell dormancy
- (2015) Anil Sadarangani et al. Journal of Translational Medicine
- β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) A M Eiring et al. LEUKEMIA
- Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
- (2015) L Lu et al. LEUKEMIA
- Hedgehog Signaling in the Maintenance of Cancer Stem Cells
- (2015) Catherine Cochrane et al. Cancers
- From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies
- (2015) Maria Ciccone et al. Frontiers in Oncology
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
- (2014) Young Choi et al. CURRENT PHARMACEUTICAL DESIGN
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2014) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
- (2014) M Agrawal et al. LEUKEMIA
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
- (2014) L. Ma et al. Science Translational Medicine
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia
- (2013) Elisa Leo et al. PLoS One
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
- (2011) W. Warsch et al. BLOOD
- The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
- (2010) F. Palandri et al. HAEMATOLOGICA
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4
- (2009) Momoko Suzuki et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Molecular biology of bcr-abl1-positive chronic myeloid leukemia
- (2008) A. Quintas-Cardama et al. BLOOD
- Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
- (2008) S. Branford et al. BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started